赵子贤先生先后在Pharmacia、Amgen、AstraZeneca等多(duō)家世界500强制药企业和大、中(zhōng)型生物(wù)技(jì )术公(gōng)司中(zhōng)成功创建和有(yǒu)效领导了全球性和區(qū)域性药物(wù)安(ān)全部门、药物(wù)安(ān)全监测团队和药物(wù)流行病學(xué)团队，并有(yǒu)效地管理(lǐ)了药物(wù)临床开发和市场协作(zuò)伙伴的药物(wù)安(ān)全工(gōng)作(zuò)以及药物(wù)安(ān)全供应商(shāng)管理(lǐ)。

Medical PhD, epidemiologist, with 25 years of experience in global innovative drugs development as senior manager, has proven multi-professional work, scientific research and management capabilities, including clinical research and development of innovative drugs, pharmacovigilance and Safety, pharmacoepidemiology, observational studies, post-marketing safety research and monitoring, post-marketing real-world evidence establishment, drug safety risk assessment management and risk minimization strategies and measures, disease management, establishment of enterprise drug safety standards and procedures and Improvement, as well as research on Pharmacoeconomics and clinical endpoint indicators.

Dr.Zhao has successfully established and effectively led the global and regional drug safety departments, drug safety monitoring teams and drug epidemiology teams in many of the world's top 500 pharmaceutical companies and large and medium-sized biotechnology companies such as Pharmacia, Amgen, and AstraZeneca , and effectively managed the drug safety work of drug clinical development and market collaboration partners, as well as drug safety supplier management.

Mr. Zhao has profound knowledge of laws, regulations and guidelines on drug development and pharmacovigilance, and has long and successful communication with FDA,EMA,NMPA,PMDA and other regulatory agencies.